Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study

OBJECTIVE: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, combining these therapies may favor prognosis in patients with a major disease presentation. We conducted a retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ysermans, Renée, Busch, Matthias H., Aendekerk, Joop P., Damoiseaux, Jan G.M.C., van Paassen, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800337/
https://www.ncbi.nlm.nih.gov/pubmed/36589266
http://dx.doi.org/10.1016/j.jtauto.2022.100178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800337/
https://www.ncbi.nlm.nih.gov/pubmed/36589266
http://dx.doi.org/10.1016/j.jtauto.2022.100178

Ejemplares similares